These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17671154)

  • 1. Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
    Johnson BE; Jackman D; Jänne PA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4628-31. PubMed ID: 17671154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
    Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
    Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
    Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
    J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways.
    Sandler A; Herbst R
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4421s-4425s. PubMed ID: 16857821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
    Milton DT; Riely GJ; Azzoli CG; Gomez JE; Heelan RT; Kris MG; Krug LM; Pao W; Pizzo B; Rizvi NA; Miller VA
    Cancer; 2007 Aug; 110(3):599-605. PubMed ID: 17577220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus exhibits efficacy as a radiosensitizer in a model of non-small cell lung cancer.
    Mauceri HJ; Sutton HG; Darga TE; Kocherginsky M; Kochanski J; Weichselbaum RR; Vokes EE
    Oncol Rep; 2012 May; 27(5):1625-9. PubMed ID: 22294050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer.
    Milton DT; Azzoli CG; Heelan RT; Venkatraman E; Gomez JE; Kris MG; Krug LM; Pao W; Rizvi NA; Dunne M; Miller VA
    Cancer; 2006 Sep; 107(5):1034-41. PubMed ID: 16878326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
    La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Ardizzoni A; Tiseo M; Capelletti M; Goldoni M; Tagliaferri S; Mutti A; Fumarola C; Bonelli M; Generali D; Petronini PG
    Biochem Pharmacol; 2009 Sep; 78(5):460-8. PubMed ID: 19427302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential role of mTOR inhibitors in non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A
    Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
    Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
    Riely GJ; Kris MG; Zhao B; Akhurst T; Milton DT; Moore E; Tyson L; Pao W; Rizvi NA; Schwartz LH; Miller VA
    Clin Cancer Res; 2007 Sep; 13(17):5150-5. PubMed ID: 17785570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer.
    Scagliotti GV; Novello S; Schiller JH; Hirsh V; Sequist LV; Soria JC; von Pawel J; Schwartz B; Von Roemeling R; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):391-5. PubMed ID: 22440336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab and erlotinib: a promising new approach to the treatment of advanced NSCLC.
    Herbst RS; Sandler A
    Oncologist; 2008 Nov; 13(11):1166-76. PubMed ID: 18997180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.